GlassScriptPhysician profile
Darci L Feiden
NPI 1194192559
$2,710.11
in general payments reported to CMS, 2019-2025
23 companies · $667 in 2025
The $667 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.39 · 2022: $87.29 · 2023: $733 · 2024: $1,187 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $396.65 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $371.66 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $310.82 | 2023-2025 | Freestyle Libre 3, Freestyle Lite |
| Lilly USA, LLC | $297.11 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $211.77 | 2023-2025 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $126.38 | 2023-2024 | Xarelto, Spravato |
| Novo Nordisk INC | $124.83 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $103.28 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $97.67 | 2021-2022 | |
| Astellas Pharma US INC | $95.33 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $91.79 | 2023-2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $90.14 | 2024 | Voquezna |
| Pfizer INC. | $60.67 | 2023-2024 | |
| Dexcom, INC. | $58.63 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.15 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $40.99 | 2025 | Nexletol |
| Boston Scientific Corporation | $39.68 | 2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $38.84 | 2023 | Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $38.63 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $16.00 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $14.25 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $13.75 | 2023 | Livalo |
| Mylan Specialty L.P. | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darci Feiden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.